SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology announced publication in Blood of updated Phase 1a/b…

Kura Oncology, Inc. · PRESS-RELEASE filed Jun 2, 2026 at 08:32 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 2, 2026 at 08:32 ET

Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitidine in relapsed/refractory NPM1-mutated AML. In venetoclax-naïve patients at the 600 mg dose, the combination showed a 70% CRc rate, 75% central MRD negativity, and median OS not reached after 10.7 months follow-up.

  • 87% ORR and 70% CRc in venetoclax-naïve R/R NPM1-m AML patients at 600 mg ziftomenib dose
  • 75% central MRD negativity (<0.01% threshold) in CRc responders with no prior venetoclax
  • Median CRc duration 9.2 months; median OS not reached after 10.7 months follow-up in venetoclax-naïve
  • 48% ORR and 24% CRc in venetoclax-experienced patients at 600 mg dose

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access